Literature DB >> 23489868

Oesophageal Chemoradiotherapy in the UK--current practice and future directions.

S Gwynne1, S Falk, S Gollins, L Wills, A Bateman, S Cummins, H Grabsch, M A Hawkins, R Maggs, S Mukherjee, G Radhakrishna, R Roy, R A Sharma, E Spezi, T Crosby.   

Abstract

The SCOPE 1 trial closed to recruitment in early 2012 and has demonstrably improved the quality of UK radiotherapy. It has also shown that there is an enthusiastic upper gastrointestinal clinical oncology community that can successfully complete trials and deliver high-quality radiotherapy. Following on from SCOPE 1, this paper, authored by a consensus of leading UK upper gastrointestinal radiotherapy specialists, attempts to define current best practice and the questions to be answered by future clinical studies. The two main roles for chemoradiotherapy (CRT) in the management of potentially curable oesophageal cancer are definitive (dCRT) and neoadjuvant (naCRT). The rates of local failure after dCRT are consistently high, showing the need to evaluate more effective treatments, both in terms of optimal local and systemic therapeutic components. This will be the primary objective of the next planned UK dCRT trial and here we discuss the role of dose escalation and systemic therapeutic options that will form the basis of that trial. The publication of the Dutch 'CROSS' trial of naCRT has shown that this pre-operative approach can both be given safely and offer a significant survival benefit over surgery alone. This has led to the development of the UK NeoSCOPE trial, due to open in 2013. There will be a translational substudy to this trial and currently available data on the role of biomarkers in predicting response to therapy are discussed. Postoperative reporting of the pathology specimen is discussed, with recommendations for the NeoSCOPE trial. Both of these CRT approaches may benefit from recent developments, such as positron emission tomography/computed tomography and four-dimensional computed tomography for target volume delineation, planning techniques such as intensity-modulated radiotherapy and 'type b' algorithms and new treatment verification methods, such as cone-beam computed tomography. These are discussed here and recommendations made for their use.
Copyright © 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23489868     DOI: 10.1016/j.clon.2013.01.006

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  10 in total

1.  NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.

Authors:  Somnath Mukherjee; Christopher N Hurt; Sarah Gwynne; Andrew Bateman; Simon Gollins; Ganesh Radhakrishna; Maria Hawkins; Jo Canham; Wyn Lewis; Heike I Grabsch; Ricky A Sharma; Wendy Wade; Rhydian Maggs; Bethan Tranter; Ashley Roberts; David Sebag-Montefiore; Timothy Maughan; Gareth Griffiths; Tom Crosby
Journal:  BMC Cancer       Date:  2015-02-12       Impact factor: 4.430

2.  Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy.

Authors:  Lucy Wills; Rhydian Maggs; Geraint Lewis; Gareth Jones; Lisette Nixon; John Staffurth; Tom Crosby
Journal:  Radiat Oncol       Date:  2017-11-15       Impact factor: 3.481

3.  MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype.

Authors:  Niamh Lynam-Lennon; Susan Heavey; Gary Sommerville; Becky A S Bibby; Brendan Ffrench; Jennifer Quinn; Claudia Gasch; John J O'Leary; Michael F Gallagher; John V Reynolds; Stephen G Maher
Journal:  Oncotarget       Date:  2017-02-14

4.  Driving developments in UK oesophageal radiotherapy through the SCOPE trials.

Authors:  S Gwynne; E Higgins; A Poon King; G Radhakrishna; L Wills; S Mukherjee; Maria Hawkins; G Jones; J Staffurth; T Crosby
Journal:  Radiat Oncol       Date:  2019-02-04       Impact factor: 3.481

5.  Value of individual surgeon performance metrics as quality assurance measures in oesophagogastric cancer surgery.

Authors:  A G M T Powell; J Wheat; N Patel; D Chan; A Foliaki; S A Roberts; W G Lewis
Journal:  BJS Open       Date:  2019-11-04

6.  MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.

Authors:  Becky A S Bibby; John V Reynolds; Stephen G Maher
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

7.  The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation.

Authors:  Rhys Carrington; John Staffurth; Samantha Warren; Mike Partridge; Chris Hurt; Emiliano Spezi; Sarah Gwynne; Maria A Hawkins; Thomas Crosby
Journal:  Radiat Oncol       Date:  2015-11-19       Impact factor: 3.481

8.  The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.

Authors:  Samantha Cox; Christopher Hurt; Tal Grenader; Somnath Mukherjee; John Bridgewater; Thomas Crosby
Journal:  Radiother Oncol       Date:  2017-09-08       Impact factor: 6.280

9.  Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma.

Authors:  A G M T Powell; C Chin; A H Coxon; A Chalishazar; A Christian; S A Roberts; W G Lewis
Journal:  BJS Open       Date:  2020-03-31

10.  Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer.

Authors:  Samantha Warren; Mike Partridge; Rhys Carrington; Chris Hurt; Thomas Crosby; Maria A Hawkins
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-01       Impact factor: 7.038

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.